Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.

An anonymous commenter opposes the approval of Moderna's mRNA influenza vaccine, requesting that the VRBPAC defer its final vote. The commenter argues that shared clinical infrastructure and overlapping mRNA trials with the same sponsor create unresolvable conflicts of interest and compromise the integrity of the trial data.

The commenter provides a critique of the disclosure process for a scientific publication, arguing that administrative errors in conflict-of-interest forms undermine scientific confidence. The comment focuses on the systemic failures of journal editorial oversight rather than taking a specific position on the safety or effectiveness of the MFLUSIVA vaccine.